Literature DB >> 32439609

Advances in the computational development of androgen receptor antagonists.

Xueping Hu1, Xin Chai2, Xuwen Wang2, Mojie Duan3, Jinping Pang2, Weitao Fu2, Dan Li4, Tingjun Hou5.   

Abstract

The androgen receptor is a ligand-dependent transcriptional factor and an essential therapeutic target for prostate cancer. Competitive binding of antagonists to the androgen receptor can alleviate aberrant activation of the androgen receptor in prostate cancer. In recent years, computer-aided drug design has played an essential part in the discovery of novel androgen receptor antagonists. This review summarizes the recent advances in the discovery of novel androgen receptor antagonists through computer-aided drug design approaches; and discusses the applications of molecular modeling techniques to understand the resistance mechanisms of androgen receptor antagonists at the molecular level.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2020        PMID: 32439609     DOI: 10.1016/j.drudis.2020.04.004

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  8 in total

1.  Discovery of novel DprE1 inhibitors via computational bioactivity fingerprints and structure-based virtual screening.

Authors:  Xue-Ping Hu; Liu Yang; Xin Chai; Yi-Xuan Lei; Md Shah Alam; Lu Liu; Chao Shen; De-Jun Jiang; Zhe Wang; Zhi-Yong Liu; Lei Xu; Kang-Lin Wan; Tian-Yu Zhang; Yue-Lan Yin; Dan Li; Dong-Sheng Cao; Ting-Jun Hou
Journal:  Acta Pharmacol Sin       Date:  2021-10-19       Impact factor: 7.169

2.  Androgen Receptor Protein Degradation in the Treatment of Castration-Resistant Prostate Cancer.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2021-02-09       Impact factor: 4.345

3.  Androgen Receptor Degradation for Therapeutic Intervention of Prostate Cancer Drug Resistance.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2021-03-17       Impact factor: 4.345

4.  Modulating Androgen Receptor in the Therapeutic Intervention for Prostate Cancer and Kennedy's Disease.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2021-04-15       Impact factor: 4.345

5.  Discovery of Novel GR Ligands toward Druggable GR Antagonist Conformations Identified by MD Simulations and Markov State Model Analysis.

Authors:  Xueping Hu; Jinping Pang; Jintu Zhang; Chao Shen; Xin Chai; Ercheng Wang; Haiyi Chen; Xuwen Wang; Mojie Duan; Weitao Fu; Lei Xu; Yu Kang; Dan Li; Hongguang Xia; Tingjun Hou
Journal:  Adv Sci (Weinh)       Date:  2021-11-26       Impact factor: 16.806

6.  Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors.

Authors:  Mariia Radaeva; Huifang Li; Eric LeBlanc; Kush Dalal; Fuqiang Ban; Fabrice Ciesielski; Bonny Chow; Helene Morin; Shannon Awrey; Kriti Singh; Paul S Rennie; Nada Lallous; Artem Cherkasov
Journal:  Cells       Date:  2022-09-07       Impact factor: 7.666

7.  Conformational dynamics of androgen receptors bound to agonists and antagonists.

Authors:  Hyo Jin Gim; Jiyong Park; Michael E Jung; K N Houk
Journal:  Sci Rep       Date:  2021-08-05       Impact factor: 4.379

8.  Discovery of a novel nonsteroidal selective glucocorticoid receptor modulator by virtual screening and bioassays.

Authors:  Jin-Ping Pang; Xue-Ping Hu; Yun-Xia Wang; Jia-Ning Liao; Xin Chai; Xu-Wen Wang; Chao Shen; Jia-Jia Wang; Lu-Lu Zhang; Xin-Yue Wang; Feng Zhu; Qin-Jie Weng; Lei Xu; Ting-Jun Hou; Dan Li
Journal:  Acta Pharmacol Sin       Date:  2022-02-02       Impact factor: 7.169

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.